SCHEMBL6095839

SCHEMBL6095839

C[C@H](NC(=O)c1nc(N2CCCCS2(O)O)n(C)c(=O)c1O)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
POLB P06746 1/20 0.45
HTT P42858 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
THRB P10828 1/20 0.42
TP53 P04637 2/20 0.42
MAPT P10636 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
PHGDH O43175 1/20 0.40
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA2B P29275 1/20 0.38
BACE1 P56817 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6095305 1.00 ALDH1A1 (0.45) ALDH1A1POLBHTTL3MBTL1THRB
SCHEMBL6093763 0.91 L3MBTL1 (0.37) ALDH1A1POLBHTTL3MBTL1THRB
SCHEMBL6095162 0.91 SMN1; SMN2 (0.38) ALDH1A1POLBHTTL3MBTL1THRB
SCHEMBL6095582 0.91 MAOA (0.43) ALDH1A1POLBHTTPHGDHNPC1
SCHEMBL6094125 0.91 ALDH1A1 (0.40) ALDH1A1POLBHTTL3MBTL1SMN1; SMN2
SCHEMBL6095823 0.90 PHGDH (0.47) ALDH1A1POLBHTTL3MBTL1THRB
SCHEMBL6095294 0.90 PHGDH (0.47) ALDH1A1POLBHTTL3MBTL1THRB
SCHEMBL6094063 0.90 MEN1 (0.42) ALDH1A1POLBHTTL3MBTL1PHGDH
SCHEMBL6094437 0.89 CLK1 (0.39) TP53MAPTPHGDHNPC1MEN1
SCHEMBL6094529 0.88 TACR3 (0.41) ALDH1A1HTTLMNACYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135467-B2 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY (US) 2006-11-14 US claimed
US-20040204498-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-10-14 US claimed
US-7135467-B2 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY (US) 2006-11-14 US disclosed
US-20040204498-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204498-A1 HIV integrase inhibitors IMPDH1, TYMP, REV1 ALDH1A1 483/4885POLB 23/4885HTT 4761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.